PHILADELPHIA, January 4, 2012: Morgan Lewis today announced that Steven A. Reed—the former Vice President and Deputy General Counsel at Cephalon, Inc.—has joined the firm as a partner in its Litigation Practice, resident in Philadelphia. In late 2011, Cephalon became part of Teva Pharmaceuticals, forming a combined company with a significant presence in over 60 countries and approximately $20 billion in revenues.
"Steve brings a wealth commercial litigation experience, with an emphasis on high-profile securities, corporate governance and antitrust litigation, in a broad range of industries, including life sciences, energy, technology, transportation, and financial services," noted Jami McKeon, leader of the Litigation practice at Morgan Lewis. "He is an outstanding litigator with strong business acumen who will be an asset to our clients in the Delaware Valley and nationally," added J. Gordon Cooney, Jr., Managing Partner of the firm's Philadelphia office.
While at Cephalon, Mr. Reed was responsible for overseeing all of the company's litigation, including three Hatch-Waxman patent trials during a 12-month period involving products with combined annual revenues of approximately $1.5 billion; high-profile antitrust litigation brought by the FTC, direct purchaser classes, and competitors relating to pay-for-delay Hatch-Waxman settlements; several third-party payor class actions involving off-label marketing; and a number of derivative and securities lawsuits. Prior to joining Cephalon, he was a partner in private practice at a firm with offices in Philadelphia and Washington, D.C.